Steve Couldwell, chief executive of Tissue Regenix PLC (LON:TRX), tells Proactive that 2017 has been a year of transformation, boosted by the acquisition of CellRight.
"That was the transformation the company really needed, and the integration of that business has gone extremely well ... we are now in the position of really trying to kick on in 2018'', Couldwell says.
Since the end of the reporting period, the group's announced strategic partnerships with ARMS Medical for DermaPure and with Arthrex for the distribution of CellRight's 'BioRinse' portfolio.
Meet ANGLE plc, Faron Pharmaceuticals Ltd, Alliance Pharma plc, Clinigen Group PLC and Avacta Group Plc at our event,London, 05 April 2018.Register here >>